Obesity – Page 3 – Talk Bio

Actionable Insights Powered by AI

Pressure On, Purpose Questioned as Second Round of FDA Priority Review Vouchers Revealed

2 months ago talkbio0Tagged Anemia, Sickle Cell, Biosimilars, Commissioner 's National Priority Voucher, Drug Approval, drug price, eli lilly, erbB-2 Receptor, Malignant neoplasm of lung, Obesity, Priority Review, public health medicine (field), Tuberculosis, Drug-Resistant, United States Food and Drug Administration, voucher program

FDA; Commissioner’s National Priority Voucher; priority review; drug approval; voucher program; Eli Lilly; Novo Nordisk; her2 lung cancer; obesity drugs; drug-resistant tuberculosis; sickle cell disease; biosimilars; public health; drug pricing; regulatory controversy

Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama

2 months ago talkbio0Tagged Acquisition, bidding war, CVR, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, regulatory certainty

Pfizer; Metsera; acquisition; Novo Nordisk; bidding war; obesity drugs; GLP-1; CVR; regulatory certainty

Zealand Pharma Pauses Development of GLP-1/GLP-2 Dual Agonist Dapiglutide for Obesity

2 months ago talkbio0Tagged Agonist, Clinical Development, Dapiglutide, drug market, GLP-1/GLP-2, Obesity, obesity therapy, petrelintide, pipeline management, Zealand Pharma

Zealand Pharma; dapiglutide; GLP-1/GLP-2 dual agonist; obesity therapy; clinical development; obesity drug market; pipeline management; petrelintide; survodutide

Pfizer Triumphs Over Novo Nordisk with $10B Bid to Acquire Metsera

2 months ago talkbio0Tagged Acquisition, Approved, bidding war, Drug Industry, Glucagon-Like Peptide 1, Metsera, Nordisk, Obesity, Pfizer, shareholder

Pfizer; Novo Nordisk; Metsera; obesity drugs; GLP-1; acquisition; bidding war; shareholder approval; pharmaceutical industry

Delaware Court Denies Pfizer’s Bid to Block Novo Nordisk-Metsera Deal

2 months ago talkbio0Tagged Antitrust, Delaware Court, merger agreement, Metsera, Nordisk, Obesity, Pfizer, restraining order, Transitory, United States Federal Trade Commission

Delaware Court; Pfizer; Novo Nordisk; Metsera; temporary restraining order; merger agreement; antitrust; FTC; obesity drugs

Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers

3 months ago talkbio0Tagged Acquisition, Antitrust, bidding war, Disputes, Dominance, Glucagon-Like Peptide 1, Legal, Market, Metsera, Novo Nordisk, Obesity, Pfizer

Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes

Novo Execs Face Skeptical Analysts Amid Metsera Buyout Drama

3 months ago talkbio0Tagged Acquisition, analysts, Antitrust, Buyout, CEO Mike, lawsuit, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; acquisition; Pfizer; buyout; obesity drugs; analysts; lawsuit; antitrust; CEO Mike Doustdar

Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

3 months ago talkbio0Tagged drug price, Eli Lilly, Glucagon-Like Peptide 1, Medicare coverage, Novo Nordisk, Obesity, Trump administration, Wegovy, White House, Zepbound

Lilly; Novo Nordisk; White House; obesity drug prices; Medicare coverage; GLP-1 medications; Trump administration; Zepbound; Wegovy

Novo Nordisk Ups Metsera Bid to $10 Billion to Top Pfizer’s Offer

3 months ago talkbio0Tagged Acquisition, contingent value right, Diabetes, M&A, Metsera, Novo Nordisk, Obesity, Pfizer

Novo Nordisk; Metsera; Pfizer; M&A; biotech acquisition; contingent value right; obesity drugs; diabetes treatments

Metsera Calls Pfizer’s Threats ‘Nonsense’ as Rift Between Companies Widens

3 months ago talkbio0Tagged Chancery, Delaware Court, drug acquisition, Litigation, Merger, Metsera, Novo Nordisk, Obesity, Pfizer, regulatory approval

Metsera; Pfizer; Novo Nordisk; merger dispute; litigation; obesity drug acquisition; regulatory approval; Delaware Court of Chancery